The Food and Drug Administration has withdrawn emergency use authorization for AstraZeneca’s Covid-19 antibody cocktail Evusheld as the treatment is not expected to neutralize the currently dominant XBB.1.5 subvariant of omicron.

The FDA had limited Evusheld’s use earlier this month for the same reason and the agency’s Thursday announcement sent U.S. shares of London-based AstraZeneca down 1.31% to $65.75.

Omicron subvariant XBB.1.5 has been spreading rapidly in the country since December and it made up nearly half of all U.S. Covid cases last week, according to government data.

[Interesting. For immune suppressed individuals, this pretty much leaves them with only infusions of antibodies as their therapeutic response, unless something else has been approved as of late. — Ed]